We are live on
!
Find out more
HP
HealthInvest Partners Portfolio holdings
AUM
$372M
1-Year Est. Return
59.89%
This Fund
S&P 500
This Quarter
Est. Return
-6.36%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.8M
AUM Growth
-$38.8M
(-37%)
Cap. Flow
-$33M
Cap. Flow
% of AUM
-49.39%
Top 10 Holdings %
Top 10 Hldgs %
84.33%
Holding
19
New
10
Increased
–
Reduced
7
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LCI
Lannett Company, Inc.
LCI
|
+$7.18M |
| 2 |
Rigel Pharmaceuticals
RIGL
|
+$6.95M |
| 3 |
Harmony Biosciences
HRMY
|
+$5.96M |
| 4 |
Utah Medical Products
UTMD
|
+$3.71M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$3.44M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ironwood Pharmaceuticals
IRWD
|
+$10.8M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$10.5M |
| 3 |
Cigna
CI
|
+$9.72M |
| 4 |
McKesson
MCK
|
+$8.8M |
| 5 |
AbbVie
ABBV
|
+$8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ironwood Pharmaceuticals
IRWD
$683M
| $8.95M | 13.4% |
685,000
-835,000
| -55% | -$10.8M |
|
2
Supernus Pharmaceuticals
SUPN
$2.73B
| $8.93M | 13.38% |
335,000
-195,000
| -37% | -$5.23M |
|
3
Accuray
ARAY
$32.8M
| $7.35M | 11% |
1,860,000
-440,000
| -19% | -$1.75M |
|
|
4
Harmony Biosciences
HRMY
$2.23B
| $7.09M | 10.62% |
+185,000
| New | +$5.96M |
|
|
5
Rigel Pharmaceuticals
RIGL
$756M
| $6.41M | 9.6% |
+176,500
| New | +$6.95M |
|
|
LCI
6
DELISTED
Lannett Company, Inc.
LCI
| $5.33M | 7.98% |
+443,750
| New | +$7.18M |
|
|
7
Utah Medical Products
UTMD
$227M
| $3.9M | 5.84% |
+42,000
| New | +$3.71M |
|
|
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
| $3.34M | 5.01% |
+220,000
| New | +$3.44M |
|
9
Aldeyra Therapeutics
ALDX
$96.5M
| $2.72M | 4.08% |
+310,000
| New | +$2.85M |
|
10
Evolus
EOLS
$407M
| $2.29M | 3.42% |
+300,000
| New | +$3.1M |
|
11
Cencora
COR
$61.7B
| $1.67M | 2.5% |
+14,000
| New | +$1.68M |
|
12
Bristol-Myers Squibb
BMY
$130B
| $1.66M | 2.48% |
28,000
-119,000
| -81% | -$7.84M |
|
|
13
AbbVie
ABBV
$435B
| $1.62M | 2.42% |
15,000
-70,000
| -82% | -$8M |
|
|
14
McKesson
MCK
$103B
| $1.59M | 2.39% |
8,000
-44,000
| -85% | -$8.8M |
|
15
Cardinal Health
CAH
$56B
| $1.58M | 2.37% |
32,000
-138,000
| -81% | -$7.49M |
|
16
UroGen Pharma
URGN
$2.26B
| $1.26M | 1.89% |
+75,000
| New | +$1.19M |
|
|
LJPC
17
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $1.08M | 1.61% |
+270,000
| New | +$1.07M |
|
|
18
Cigna
CI
$71.5B
| – | – |
-41,000
| Closed | -$9.72M |
|
|
19
Vertex Pharmaceuticals
VRTX
$123B
| – | – |
-52,000
| Closed | -$10.5M |
|
Similar funds
KP
TCM
SAAM
PAA
PC
BOCH
GIP
PC
HealthInvest Partners's Q3 2021 Portfolio in Review
As of Q3 2021, HealthInvest Partners held 19 positions worth $66.8M, down 37% from $106M the previous quarter. Its ten largest holdings account for 84% of the portfolio.
HealthInvest Partners withdrew a net $33M in Q3 2021, closing 2 positions and reducing 7 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $10.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, HealthInvest Partners opened a new position in Lannett Company, Inc. worth $5.33M.
- HealthInvest Partners's largest Q3 2021 buy was Lannett Company, Inc.: 443,750 shares worth $5.33M.
- HealthInvest Partners's biggest Q3 2021 reduction was Ironwood Pharmaceuticals, cutting an estimated $10.8M.
- HealthInvest Partners fully exited Vertex Pharmaceuticals in Q3 2021, selling an estimated $10.5M.
- HealthInvest Partners's ten largest holdings make up 84% of its $66.8M portfolio in Q3 2021.
- HealthInvest Partners opened 10 new positions and closed 2 in Q3 2021.
- HealthInvest Partners's portfolio value fell 37% quarter-over-quarter to $66.8M.
Based on HealthInvest Partners's 13F filing for Q3 2021, filed 8 Nov 2021.